Detalles de la búsqueda
1.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer;
127(12): 2015-2024, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739457
2.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Br J Haematol;
177(5): 741-750, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28419408
3.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol;
92(10): 1037-1046, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28675513
4.
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
Br J Haematol;
185(5): 954-957, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30407614
5.
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.
Haematologica;
99(6): 1078-87, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24561793
6.
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.
Haematologica;
104(1): e4-e8, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30076178
7.
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.
J Immunol;
186(10): 6044-55, 2011 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21498665
8.
Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.
Pituitary;
15(2): 209-14, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21503687
9.
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Haematologica;
101(7): e280-3, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27056923
10.
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease.
Haematologica;
96(7): 1015-23, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21486864
11.
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Blood;
122(13): 2286-8, 2013 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24072851
12.
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study.
Sci Rep;
10(1): 9156, 2020 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32514107
13.
Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.
Blood;
120(9): 1954-7, 2012 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22936740
14.
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
Ann Hematol;
88(9): 855-61, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19189105
15.
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
Oncol Rep;
21(4): 1045-52, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19288007
16.
Purpura as the initial presentation for small-cell lung cancer.
Onkologie;
32(5): 277-9, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19420975
17.
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
Cancer Med;
8(18): 7567-7576, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31657156
18.
Soluble molecules and bone metabolism in multiple myeloma: a review.
Clin Cases Miner Bone Metab;
5(1): 67-70, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22460849
19.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol;
4(3): e127-e136, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28162984
20.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
J Clin Oncol;
35(14): 1591-1597, 2017 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350519